Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06967831

Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells

Sponsor: Charite University, Berlin, Germany

View on ClinicalTrials.gov

Summary

In this project, the investigators are using iPSC lines derived from patients with Leigh syndrome that carry mutations in the mitochondrial (mtDNA) and in the nuclear DNA (nDNA) to reprogram them into neural progenitor cells and into dopaminergic neurons. The researchers are using this experimental system to screen FDA (Food and Drug Administration, USA) and EMA (European Medicines Agency) approved drugs for a positive effect on Leigh patient-derived neuronal cells (drug repurposing) using various biochemical, optic, and morphological outcome measures. Confirmed positive hits may be used for compassionate off-label use in Leigh patients when no standard treatment is available.

Official title: Using iPSC Derived Human Basal Ganglia Neurons From Patients With Leigh Syndrome for Metabolic Studies, Assay Development, and Drug Repurposing.

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

80

Start Date

2020-03-01

Completion Date

2030-02-28

Last Updated

2025-05-13

Healthy Volunteers

No

Interventions

PROCEDURE

skin biopsy

Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.

OTHER

generation of iPSCs

Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.

DIAGNOSTIC_TEST

blood drawing

Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.

DRUG

off-label compassionate drug use

In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.

Locations (2)

Universitätsklinikum Düsseldorf

Düsseldorf, North Rhine-Westphalia, Germany

Charite - Universtaetsmedizin Berlin

Berlin, State of Berlin, Germany